Osteoarthritis Therapeutics Market Report and Forecast 2024-2032

The osteoarthritis therapeutics market size was valued at USD 9.1 billion in 2023, driven by the increasing geriatric population across the globe. The market size is anticipated to grow at a CAGR of 8.7% during the forecast period of 2024-2032 to achieve a value of USD 19.1 billion by 2032.

Osteoarthritis Therapeutics: Introduction

Osteoarthritis therapeutics refer to the various treatment options and approaches used to manage and alleviate the symptoms of osteoarthritis, a common degenerative joint disease characterized by the breakdown of cartilage in the joints. Osteoarthritis primarily affects the knees, hips, hands, and spine and can result in joint pain, stiffness, reduced mobility, and decreased quality of life. The choice of therapeutic interventions depends on the severity of the condition, the affected joints, and individual patient needs.

Key Trends in the Osteoarthritis Therapeutics Market

Here are some key trends influencing the market:

Biologics and Regenerative Therapies: The use of biologics, including platelet-rich plasma (PRP) and stem cell therapies, is a growing trend in osteoarthritis treatment. These therapies aim to promote tissue repair and regeneration.
Precision Medicine: Advancements in genomics and biomarker research are leading to the development of personalized treatment plans based on the patient's genetic and molecular profile, optimizing therapeutic outcomes.
Telemedicine and Remote Monitoring: Telehealth and remote monitoring solutions are increasingly used for patient consultations and follow-ups, making it more convenient for osteoarthritis patients to access care and track their progress.
Patient Education and Engagement: The availability of online resources and educational materials empowers patients to take an active role in managing their osteoarthritis. Healthcare providers are focusing on patient education and engagement to improve adherence to treatment plans.
Wearable Technology: Wearable devices, such as smart braces and activity trackers, are becoming valuable tools for monitoring joint health, tracking physical activity, and providing real-time feedback to patients.
Nutraceuticals and Supplements: The use of dietary supplements and nutraceuticals, such as glucosamine, chondroitin, and turmeric, is a growing trend among osteoarthritis patients seeking alternative or complementary therapies.

Osteoarthritis Therapeutics Market Segmentations

Market Breakup by Type

Hip Osteoarthritis
Spinal Osteoarthritis
Knee Osteoarthritis
Hand Osteoarthritis
Others

Market Breakup by Drug Class

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Analgesics
Corticosteroids
Hyaluronic Acid Injections
Disease-modifying Osteoarthritis Drugs
Others

Market Breakup by Doses Form

Tablets and Capsules
Injections
Creams and Gels
Others

Market Breakup by Route of Administration

Oral
Parenteral
Topical

Market Breakup by End User

Hospitals
Specialty Clinics
Homecare Settings
Others

Market Breakup by Distribution Channel

Hospitals Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Market Breakup by Region -7MM

United States
EU-4 and the United Kingdom
Japan

Osteoarthritis Therapeutics Market Overview

Here are some market drivers impacting the market:

Aging Population: The global aging population is a significant driver of the osteoarthritis therapeutics market. As individuals age, the risk of developing osteoarthritis increases, leading to a higher demand for treatments to manage the condition.
Rising Prevalence: Osteoarthritis is one of the most common musculoskeletal disorders globally, with a rising prevalence. This increase in the number of affected individuals drives the need for effective therapeutics.
Advancements in Treatment: Ongoing research and development efforts have led to the discovery of new treatment modalities, including disease-modifying drugs and regenerative therapies, which offer potential benefits for osteoarthritis patients.
Patient-Centered Care: The shift toward patient-centered care models emphasizes personalized treatment plans tailored to individual patient needs and preferences. This trend influences treatment choices and the development of patient-friendly therapeutics.
Technological Innovations: Advancements in medical technology, such as minimally invasive surgical techniques and imaging modalities, enhance the diagnosis and treatment of osteoarthritis, driving the demand for therapeutics.
Healthcare Infrastructure Development: Investments in healthcare infrastructure, especially in emerging markets, contribute to improved access to osteoarthritis diagnosis and treatment, thereby expanding the market.

Osteoarthritis Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

The major companies in the market are as follows:

Pfizer Inc.
Abbvie Inc.
Novartis AG
Amgen Inc.
Boehringer Ingelheim International GmbH.
Samsung Bioepis
Merck & Co Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Industries Ltd.
AstraZeneca PL
Zimmer Biomet
Stryker Corporation

The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

1 Preface

1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology

2 Executive Summary

3 Osteoarthritis Overview

3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway

4 Patient Profile

4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate

5 Osteoarthritis Epidemiology Analysis-7MM

5.1 Epidemiology Overview (2017-2032)
5.2 United States Osteoarthritis Epidemiology (2017-2032)
5.3 EU-4 and United Kingdom Osteoarthritis Epidemiology (2017-2032)
5.4 Japan Osteoarthritis Epidemiology (2017-2032)

6 Osteoarthritis Therapeutics Market Overview

6.1 Osteoarthritis Therapeutics Market Historical Value (2017-2023)
6.2 Osteoarthritis Therapeutics Market Forecast Value (2024-2032)

7 Osteoarthritis Therapeutics Market Landscape

7.1 Osteoarthritis Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Osteoarthritis Therapeutics: Product Landscape
7.2.1 Analysis by Therapy Type
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration

8 Osteoarthritis Therapeutics Challenges and Unmet Needs

8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps

9 Cost of Treatment

10 Osteoarthritis Therapeutics Market Dynamics

10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis

11 Osteoarthritis Therapeutics Market Segmentation

11.1 Osteoarthritis Therapeutics Market by Type
11.1.1 Market Overview
11.1.2 Hip Osteoarthritis
11.1.3 Spinal Osteoarthritis
11.1.4 Knee Osteoarthritis
11.1.5 Hand Osteoarthritis
11.1.6 Others
11.2 Osteoarthritis Therapeutics Market by Drug Class
11.2.1 Market Overview
11.2.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
11.2.3 Analgesics
11.2.4 Corticosteroids
11.2.5 Hyaluronic Acid Injections
11.2.6 Disease-modifying Osteoarthritis Drugs
11.2.7 Others
11.3 Osteoarthritis Therapeutics Market by Doses Form
11.3.1 Market Overview
11.3.2 Tablets & Capsules
11.3.3 Injections
11.3.4 Creams and Gels
11.3.5 Others
11.4 Osteoarthritis Therapeutics Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.4.4 Topical
11.5 Osteoarthritis Therapeutics Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Homecare Settings
11.5.5 Others
11.6 Osteoarthritis Therapeutics Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospitals Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
11.6.5 Others
11.7 Osteoarthritis Therapeutics Market by Region-7MM
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.4 Japan

12 United States Osteoarthritis Therapeutics Market

12.1 U.S. Osteoarthritis Therapeutics Market Historical Size (2017-2023)
12.2 U.S. Osteoarthritis Therapeutics Market Forecast Size (2024-2032)
12.3 Market Size by Drug Class

13 EU-5 and the United Kingdom Osteoarthritis Therapeutics Market

13.1 EU-5 and the United Kingdom Osteoarthritis Therapeutics Market Historical Size (2017-2023)
13.2 EU-5 and the United Kingdom Osteoarthritis Therapeutics Market Forecast Size (2024-2032)
13.3 Market Size by Drug Class

14 Japan Osteoarthritis Therapeutics Market

14.1 Japan Osteoarthritis Therapeutics Market Historical Size (2017-2023)
14.2 Japan Osteoarthritis Therapeutics Market Forecast Size (2024-2032)
14.3 Market Size by Drug Class

15 Regulatory Framework

15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA

16 Patent Analysis

16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players

17 Grants Analysis

17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization

18 Clinical Trials Analysis

18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography

19 Funding and Investment Analysis

19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography

20 Partnership and Collaborations Analysis

20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography

21 Supplier Landscape

21.1 Pfizer Inc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Abbive Inc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Novartis AG
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Amgen Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Boehringer Ingelheim International GmbH.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 F. Hoffmann-La Roche Ltd.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Merck & Co Inc.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Teva Pharmaceutical Industries Ltd.
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Sun Pharmaceutical Industries Ltd.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 AstraZeneca PL
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Zimmer Biomet
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Stryker Corporation
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications

22 Osteoarthritis Therapeutics - Distribution Model (Additional Insight)

22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment

23 Key Opinion Leaders (KOL) Insights (Additional Insight)

24 Company Competitiveness Analysis (Additional Insight)

24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies

25 Payment Methods (Additional Insight)

25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket

Companies Mentioned

Pfizer Inc.
Abbive Inc.
Novartis AG
Amgen Inc.
Boehringer Ingelheim International GmbH.
F. Hoffmann-La Roche Ltd. Merck & Co Inc.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
AstraZeneca PL
Zimmer Biomet
Stryker Corporation

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2930EUR$2,999USD£2,446GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€3907EUR$3,999USD£3,262GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€5861EUR$5,999USD£4,893GBP